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Conclusion: Salvage EBRT after SIRT was effective for HCC 
patients with PVT. The 3D dose summation and BED-DVH of 
combined therapy help to predict liver toxicity. By carefully 
selecting patients, the combined therapy bring acceptable 
toxicities incidence.  
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Purpose or Objective: Unflattened surface HDR 
Brachytherapy applicators commonly suffer from dose fall off 
on the side of the dose distribution. Recent research 
documented that in addition to missing dose at the side of 
the applicator vertical type HDR Brachytherapy surface 
applicators are subject to underdose in the middle of the 
treatment region. This artifact is clinically relevant because 
tumor cells in the middle of the treated area can end up 
irradiated insufficiently. In this work we present a surface-
dose compensation body generated with a 3D printer that 
specifically addresses the dose irregularities of a vertical 
type HDR Brachytherapy surface applicator. In order to 
overcome the limitation of increased treatment time of 
applicator flattening for horizontal type applicators we 
utilize the possibility of using a source position nearer to the 
surface to generate a flattened dose distribution together 
with reduced treatment time. 
 
Material and Methods: A 40 mm Varian VariSource 
GM11010080 applicator was used for the modification (Varian 
Medical Systems, Inc., Palo Alto, CA, USA). The source 
position is 1.5 cm from applicator tip. The depth of 
evaluation is 0.5 cm solid water material. A consumer grade 
3D printer “UP! 3D, Beijing TierTime Technology Co. Ltd.” 
was used to print out a negative form with ABS plastic. 
Lippowitz type low temperature melting metal was used to 
mold the positive form of the flattening elements. All dose 
measurements and flatness evaluations were performed with 
Gafchromic EBT3 film Lot #: 12021402 and the FilmQA 
software, flatness and symmetry toolbox (both Ashland 
Speciality Ingredients, Bridgewate, NJ, USA). 
 
Results: The generated compensation element is of toroidal 
shape, for the standard source position 1.5 cm from appliator 
tip, has a maximum thickness of 1.5 mm in surface direction. 
The output of the applicator with flattening element 
occurred to be 75% of the unflattened one. The diameter of 
80% nominal dose area increased from 35.2 mm with the 
unflattended applicator to 50.2 mm with the flattening 
element in place. The asymetric central low-dose artefact 
can be compensated to a clinical acceptable minimum dose. 
When utilizing the source position 1 cm from tip a prototype 
filter could bring the width of the 80% dose area to 45.0 mm, 
above the nominal applicator size, and output to 112 % of an 
unflattened applicator. The position 0.5 cm from tip is still 
considered flattable with increased low dose area in out of 
field tissue due to applicator geometry when quick treatment 
is of clinical interest. The first soure position on applicator 
tip is not flattable for clinical use. 
 
Conclusion: The presented prototype of a dose compensation 
body can remove the dose artefacts of a vertical type HDR 
Brachytherapy surface applicator including the clinical 
relevant underdosed central region. With the appropriate 
flattening body it is now possible to utilize a source position 
nearer to surface and compensate for dose output loss when 
using a dose flattening element. 
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Purpose or Objective: Skin cancer is the most common 
malignancy in white population. The most prevalent 
histologies are basal cell carcinoma (BCC) followed by 
squamous cell carcinoma (SCC). They are locally aggressive 
lesions that rarely metastasize and their prognosis depends 
on local control. Due to their localization and superficial 
nature, cosmetic result of the treatment is of primary 
importance. High-Dose-Rate brachytherapy (HDR-BT) is a safe 
and effective treatment option for these carcinomas and for 
other skin lesions. There are two main techniques for its 
delivery: interstitial brachytherapy and plesiotherapy.  
We have evaluated early local control, acute toxicity and 
cosmetic outcomes in all patients treated with HDR-BT in our 
center. 
 
Material and Methods: We assessed 47 patients who had 52 
skin lesions. There were 29 SCCs, 14 BCCs, 4 keloid scars, 3 
adenocarcinomas,1 lentigo maligna and 1 Merkel cell 
carcinoma. Median age of treated patients was 78 years (34-
93). Data was collected prospectively.All lesions were 
treated with HDR-BT at our institution between December 
2014 and August 2015 by interstitial brachytherapy or 
plesiotherapy. Average total dose delivered was 35,63 Gy and 
Median dose delivered was 40,5 Gy.  
Acute toxicity was graded using the Common Terminology 
Criteria for Adverse Events, version 4.0 and cosmetic 
outcomes were classified using the Radiation Therapy 
Oncology Group cosmetic rating scale. 
 
Results: Average follow-up from completion of treatment 
was 5.5 months (2-10.1). The overall crude recurrence rate 
was 3,8% (n = 2). Grade 0 acute toxicity was observed in 7.7% 
of treated lesions (n = 4), grade 1 in 63.5% (n = 33), grade 2 
in 21.2% (n = 11) and grade 3 in 7.7% (n = 4). No acute 
toxicity greater than grade 3 was observed. All acute toxic 
events were resolved between the first and the second month 
after brachytherapy. Cosmetic results were excellent or good 
in 92.3% of the cases (n = 48), fair in 3.8% (n = 2) and not 
evaluable in 2 patients whose tumours were not cured. 
 
 
